Tandem Diabetes Care

Tandem Diabetes Care

TNDM· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -39.0% in FY2025

John Sheridan is the CEO of Tandem Diabetes Care and was paid $6.9M in FY2025 (Dec), down 20%.

Pay$100 in the stock at the end of FY20 → $23
CEO pay is from each Tandem Diabetes Care proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1John SheridanFY2025
  2. 2Mark NovaraFY2025
  3. 3Leigh VossellerFY2025
  4. 4Elizabeth GasserFY2025
  5. 5Shannon HansenFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Tandem Diabetes Care paid its 5 named executives $14.7M in total in FY2025 (Dec). CEO John Sheridan was paid $6.9M of that.

Name
John SheridanPresident and Chief Executive Officer
Mark NovaraExecutive Vice President, Chief Commercial Officer
Leigh VossellerExecutive Vice President, Chief Financial Officer and Treasurer
Elizabeth GasserExecutive Vice President, Chief Strategy and Product Officer
Shannon HansenExecutive Vice President, Chief Legal, Privacy and Compliance Officer and SecretaryNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Tandem Diabetes Care names 18 peer companies for pay. Pay versus performance data of Tandem Diabetes Care for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Kathleen Mcgroddy-GoetzDirector · 5 yr on the boardIndependentCybersecurity and Data Privacy Oversight, Nominating and Corporate Governance—Paid as an executive
  • Joao MalagueiraDirector · 3 yr on the boardIndependentAudit—Paid as an executive
  • Myoungil ChaDirector · 3 yr on the boardIndependentCompensation—Paid as an executive
  • Sandra BeaverDirector · 0 yr on the boardIndependentAudit, Cybersecurity and Data Privacy Oversight—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Tandem Diabetes Care Division head pay rose 175% to $2.2M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Tandem Diabetes Care CFO pay fell 12% to $2.2M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Tandem Diabetes Care CEO pay fell 20% to $6.9M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Tandem Diabetes Care Executive Vice President, Chief Strategy and Product Officer pay fell 13% to $1.7M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  5. Board
    Sandra Beaver joined the board of Tandem Diabetes Care. Sandra Beaver sits on no other public board.
    3
  6. Pay
    Tandem Diabetes Care Executive Vice President, Chief Administrative Officer pay rose 61% to $2.0M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Tandem Diabetes Care Division head pay fell 70% to $802.7K. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Tandem Diabetes Care CFO pay rose 98% to $2.5M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Tandem Diabetes Care CEO pay rose 83% to $8.5M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Tandem Diabetes Care CEO pay rose 11% to $6.4M. The stock fell 70% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Tandem Diabetes Care Executive Vice President, Chief Strategy and Product Officer pay rose 60% to $2.0M. The stock rose 22% in FY2024 (Dec).
    DEF 14A
  12. Pay
    Tandem Diabetes Care Executive Vice President, Chief Administrative Officer pay fell 30% to $1.2M. The stock fell 34% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Tandem Diabetes Care CFO pay fell 29% to $1.3M. The stock fell 34% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Tandem Diabetes Care CEO pay fell 27% to $4.7M. The stock fell 34% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Tandem Diabetes Care Executive Vice President, Chief Strategy and Product Officer pay fell 26% to $1.3M. The stock fell 34% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Tandem Diabetes Care Division head pay fell 29% to $1.3M. The stock fell 34% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Tandem Diabetes Care Division head pay fell 27% to $1.3M. The stock fell 34% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 7, 2026FY2025
Annual report10-KFeb 19, 2026FY2025
Proxy statementDEF 14AApr 8, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 9, 2024FY2023
Annual report10-KFeb 21, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data